Transcriptomic Profiling Identifies DCBLD2 as a Diagnostic and Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma

被引:11
|
作者
Feng, Zengyu [1 ,2 ,3 ]
Li, Kexian [1 ,2 ]
Wu, Yulian [3 ]
Peng, Chenghong [1 ,2 ]
机构
[1] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Pancreat Dis Ctr,Dept Gen Surg, Shanghai, Peoples R China
[2] Shanghai Jiao Tong Univ, Sch Med, Res Inst Pancreat Dis, Shanghai, Peoples R China
[3] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Gen Surg, Hangzhou, Peoples R China
基金
中国国家自然科学基金;
关键词
DCBLD2; pancreatic ductal adenocarcinoma; prognosis; diagnosis; extracellular vesicles; immune infiltrates; GENE-EXPRESSION; UP-REGULATION; STEM-CELLS; CANCER; ESDN; PROGRESSION;
D O I
10.3389/fmolb.2021.659168
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Background: Accumulating evidence shows that the elevated expression of DCBLD2 (discoidin, CUB and LCCL domain-containing protein 2) is associated with unfavorable prognosis of various cancers. However, the correlation of DCBLD2 expression value with the diagnosis and prognosis of pancreatic ductal adenocarcinoma (PDAC) has not yet been elucidated. Methods: Univariate Cox regression analysis was used to screen robust survival-related genes. Expression pattern of selected genes was investigated in PDAC tissues and normal tissues from multiple cohorts. Kaplan-Meier (K-M) survival curves, ROC curves and calibration curves were employed to assess prognostic performance. The relationship between DCBLD2 expression and immune cell infiltrates was conducted by CIBERSORT software. Biological processes and KEGG pathway enrichment analyses were adopted to clarify the potential function of DCBLD2 in PDAC. Results: Univariate analysis, K-M survival curves and calibration curves indicated that DCBLD2 was a robust prognostic factor for PDAC with cross-cohort compatibility. Upregulation of DCBLD2 was observed in dissected PDAC tissues as well as extracellular vesicles from both plasma and serum samples of PDAC patients. Both DCBLD2 expression in tissue and extracellular vesicles had significant diagnostic value. Besides, DCBLD2 expression was correlated with infiltrating level of CD8(+) T cells and macrophage M2 cells. Functional enrichment revealed that DCBLD2 might be involved in cell motility, angiogenesis, and cancer-associated pathways. Conclusion: Our study systematically analyzed the potential diagnostic, prognostic and therapeutic value of DCBLD2 in PDAC. All the findings indicated that DCBLD2 might play a considerably oncogenic role in PDAC with diagnostic, prognostic and therapeutic potential. These preliminary results of bioinformatics analyses need to be further validated in more prospective studies.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma
    Wang, Huanyu
    Mao, Weilin
    Lou, Wenhui
    Jin, Dayong
    Wu, Wenchuan
    Wang, Dansong
    Kuang, Tiantao
    Rong, Yefei
    Xu, Xuefeng
    Zhang, Lei
    JOURNAL OF CANCER, 2022, 13 (05): : 1501 - 1511
  • [32] SFRP5 as a prognostic biomarker for patients with pancreatic ductal adenocarcinoma
    Zhou, Wence
    Tian, Ming
    Hu, Jinjing
    Li, Lihong
    He, Yong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (03): : 3442 - 3447
  • [33] Pentraxin 3: A stromal derived diagnostic biomarker for pancreatic ductal adenocarcinoma
    Goulart, Michelle R.
    Watt, Jennifer
    Siddique, Imran
    Lawor, Rita
    Dowe, Thomas
    Bhattacharya, Satyajit
    Crnogorac-Jurcevic, Tatjana
    Allavena, Paola
    Scarpa, Aldo
    Kocher, Hemant M.
    CANCER RESEARCH, 2019, 79 (13)
  • [34] Serum laminin γ2 monomer as a novel diagnostic and prognostic marker for pancreatic ductal adenocarcinoma
    Takeshi Terashima
    Kouki Nio
    Naohiko Koshikawa
    Makoto Ueno
    Tadashi Toyama
    Masaki Miyazawa
    Tomoyuki Hayashi
    Akihiro Seki
    Hidetoshi Nakagawa
    Noriho Iida
    Shinya Yamada
    Hajime Takatori
    Tetsuro Shimakami
    Toru Yoshimura
    Eisaku Yoshida
    Masatoshi Nakagawa
    Motoharu Seiki
    Taro Yamashita
    BJC Reports, 3 (1):
  • [35] Biomarker detection in pancreatic ductal adenocarcinoma
    Klett, H.
    Klose, M.
    Kowar, S.
    Bronsert, P.
    Kuesters, S.
    Werner, M.
    Christoph, P.
    Busch, H.
    Boerries, M.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S177 - S178
  • [36] Serum high mobility group box-1 is a powerful diagnostic and prognostic biomarker for pancreatic ductal adenocarcinoma
    Chung, Hye Won
    Lim, Jong-Baeck
    Jang, Sunphil
    Lee, Kyong Joo
    Park, Kyung Hwa
    Song, Si Young
    CANCER SCIENCE, 2012, 103 (09): : 1714 - 1721
  • [37] Protein biomarker for pancreatic ductal adenocarcinoma
    Burki, Talha K.
    LANCET ONCOLOGY, 2017, 18 (09): : E511 - E511
  • [38] Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma
    Alhasan, Sari F.
    Haugk, Beate
    Ogle, Laura F.
    Beale, Gary S.
    Long, Anna
    Burt, Alastair D.
    Tiniakos, Dina
    Televantou, Despina
    Coxon, Fareeda
    Newell, David R.
    Charnley, Richard
    Reeves, Helen L.
    BRITISH JOURNAL OF CANCER, 2016, 115 (07) : 797 - 804
  • [39] Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma
    Sari F Alhasan
    Beate Haugk
    Laura F Ogle
    Gary S Beale
    Anna Long
    Alastair D Burt
    Dina Tiniakos
    Despina Televantou
    Fareeda Coxon
    David R Newell
    Richard Charnley
    Helen L Reeves
    British Journal of Cancer, 2016, 115 : 797 - 804
  • [40] Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma
    Munding, Johanna B.
    Adai, Alex T.
    Maghnouj, Abdelouahid
    Urbanik, Aleksandra
    Zoellner, Hannah
    Liffers, Sven T.
    Chromik, Ansgar M.
    Uhl, Waldemar
    Szafranska-Schwarzbach, Anna E.
    Tannapfel, Andrea
    Hahn, Stephan A.
    INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (02) : E86 - E95